Lung Cancer, Nonsmall Cell study: Atezolizumab vs Tocilizumab
Official title Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
ClinicalTrials.gov ID: NCT04691817
What this study is testing
What is Atezolizumab?
Atezolizumab is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for lung cancer, nonsmall cell.
Also referred to as Tecentriq.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to at least 1 line of therapy
- Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ECOG PS 0-2
You likely can't join if
- Presence of a driver mutation that is susceptible to targeted therapy
- No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- Other active invasive malignancy requiring ongoing therapy
- Evidence of progressing or untreated brain metastases
- Evidence or history of leptomeningeal disease
- Uncontrolled tumor related pain
See the full eligibility criteria
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to at least 1 line of therapy
- Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ECOG PS 0-2
- Presence of a driver mutation that is susceptible to targeted therapy
- No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- Other active invasive malignancy requiring ongoing therapy
- Evidence of progressing or untreated brain metastases
- Evidence or history of leptomeningeal disease
- Uncontrolled tumor related pain
- History of an autoimmune disease or IPF
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.